ACM
ALXO icon

ACT Capital Management’s ALX Oncology ALXO Stock Holding History

ACT Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500
Closed -$111K – 97
2021
Q3 		$111K Buy
+1,500
New +$100K 0.06% 89

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACT Capital Management's ALXO Position: Q4 2021 in Review

ACT Capital Management sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 1,500 shares — an estimated $111K sold.

ACT Capital Management first reported a position in ALXO in Q3 2021 and held it in 1 quarter. The position peaked at $111K in Q3 2021. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

  • ACT Capital Management reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
  • ACT Capital Management sold 1,500 ALX Oncology shares in Q4 2021, an estimated $111K.
  • ACT Capital Management first reported a position in ALX Oncology in Q3 2021 and held it in 1 quarter.
  • ACT Capital Management's ALX Oncology position peaked at $111K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.